BioCentury
ARTICLE | Clinical News

Samsung, Merck biosimilar of Humira shows bioequivalence

July 9, 2015 12:42 AM UTC

Samsung Bioepis Co. Ltd. said SB5, its biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:ABBV), met the primary endpoint of equivalence to its reference product in a Phase III trial to treat moderate to severe rheumatoid arthritis in patients who have received methotrexate. The primary endpoint was measured by ACR20 at week 24.

Samsung Bioepis, a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung Group (Seoul, South Korea), is developing SB5 in partnership with Merck & Co. Inc. (NYSE:MRK). ...